F-star Therapeutics Receivables

The latest receivables for FSTX is $8.1M as of September 2022. That compares with $1.9M in the prior-year period — up 320.3% year over year. Investors often review this figure alongside F-star Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, FSTX's receivables moved from $1.9M to $8.1M — a 320.3% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in F-star Therapeutics's operating scale or balance-sheet position.

A receivables figure of $8.1M for FSTX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting FSTX's receivables ($8.1M), review year-over-year change from $1.9M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack F-star Therapeutics's receivables against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.